MDxHealth Receives Additional Nasdaq Letter Over Minimum Bid Violation; Time Granted Till Dec '26
MDxHealth SA said it received another Nasdaq notification letter citing a continued minimum bid price deficiency under Nasdaq rules 5550(b)(2) and 5810(c)(3)(C). Based on market value from June 1 to July 17, 2026, it does not meet the minimum. It has until Dec. 28, 2026 to regain compliance, with shares needing a $1.00 close for 10 days. Stock closed at $0.41.
How this was made
The 30-second read
Why it matters
This is a regulatory listing-compliance update that keeps delisting risk active. The key tradable element is the specified path to regain compliance: a $1.00 closing bid for at least 10 consecutive business days, with a Dec 28, 2026 deadline and potential for additional time or delisting if not met.
Market read
Traders should reassess delisting probability and near-term volatility given the stock closed at $0.41 and Nasdaq reiterated the deficiency with a long but finite deadline.
What to watch
The article does not state any concrete plan (financing, reverse split, or bid-support actions), so traders should treat the compliance timeline as risk, not resolution.
Background
Nasdaq Rule 5550(b)(2) requires maintaining a minimum market value of $35 million, and Rule 5810(c)(3)(C) flags continued deficiency over 30 consecutive days; the company previously received a June 30, 2026 notification.
Ticker impact
Nasdaq reiterated MDxHealth’s minimum bid price deficiency under Rule 5550(b)(2), with compliance deadline extended to Dec 28, 2026.
Near-term downside risk persists while the stock trades below $1.00; volatility likely increases around compliance milestones.
The article is a fresh Nasdaq notification reiterating continued noncompliance and specifies the bid-price condition and the Dec 28, 2026 deadline.
Market effects
Adds to the broader small-cap listing-compliance risk narrative for precision diagnostics and other micro/small-cap healthcare names.
Primarily US listing risk, with potential spillover to other Nasdaq-traded microcaps facing similar bid-price thresholds.
Limited, as the event is exchange-specific and does not indicate global demand or fundamental change.
Counterpoint
The extension to Dec 28, 2026 reduces immediate delisting pressure, so the market may over-discount the risk if the company can engineer a path to a $1.00 close.
Key entities
- companyMDxHealth SA
Nasdaq-listed precision diagnostics company receiving an additional minimum bid violation notification.
- regulatorNasdaq Stock Market LLC
Exchange issuing the listing deficiency notification and compliance timeline.
